Uncategorized

AstraZeneca, Ionis slip as ATTR-CM drug fails Phase 3

Published

on

The late-stage miss is “surprising,” Stifel analysts said, given that Wainua’s mechanism of silencing transthyretin protein expression has previously proven effective.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version